Literature DB >> 7882363

Instability of microsatellites in human gliomas.

E Dams1, E J Van de Kelft, J J Martin, J Verlooy, P J Willems.   

Abstract

We have analyzed DNA obtained from 10 glioblastomas multiforme and 6 astrocytomas for microsatellite instability, using 17 different microsatellite loci dispersed over 7 different chromosomes. Six of 16 gliomas showed 1 or more microsatellite alterations in tumor DNA as compared to constitutional DNA. We observed microsatellite instability resulting in allelic shifts in 5 of 10 glioblastomas multiforme but not in any of the astrocytomas. Loss of an allele was observed in 3 glioblastomas multiforme. An imbalance in the intensity of alleles was noticed in 1 astrocytoma and in 1 glioblastoma multiforme. In 1 glioblastoma multiforme, an extra allele was present at two distinct loci. Overall, 5.3% of microsatellite analyses showed an abnormality. We conclude that microsatellite instability is present at a low grade in glioblastomas multiforme but to a lesser extent in astrocytomas. Genomic instability in human gliomas, therefore, should not be regarded as a mechanism for tumor initiation but as an evolution in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882363

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Establishment and characterization of nine human brain tumor cell lines.

Authors:  K H Shin; G Choe; Y J Park; J H Jang; H W Jung; J G Park
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Nov-Dec       Impact factor: 2.416

2.  The role of microsatellite instability in gastric low- and high-grade lymphoma development.

Authors:  P Starostik; A Greiner; S Schwarz; J Patzner; A Schultz; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Yuri E Nikiforov; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Floyd H Gilles; Allan J Yates; Tianni Zhou; Kenneth J Cohen; Jonathan L Finlay; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

4.  Genotyping of PCR-based polymorphisms and linkage-disequilibrium analysis at the NF1 locus.

Authors:  S M Purandare; R Cawthon; L M Nelson; S Sawada; W S Watkins; K Ward; L B Jorde; D H Viskochil
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

5.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 6.  The mutation rate and cancer.

Authors:  A L Jackson; L A Loeb
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

7.  Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas.

Authors:  S Lescop; A Lellouch-Tubiana; G Vassal; C Besnard-Guerin
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

8.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

9.  Distinctive mechanism for sustained TGF-β signaling and growth inhibition: MEK1 activation-dependent stabilization of type II TGF-β receptors.

Authors:  Gang Chen; Paritosh Ghosh; Dan L Longo
Journal:  Mol Cancer Res       Date:  2010-12-03       Impact factor: 5.852

Review 10.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.